[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571660":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":63,"collaborators":42,"id":66,"slug":42,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":42,"enrollmentInfo":74,"targetDuration":42,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":50,"whyStopped":42,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Kyoto University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aspirin Continuation","EXPERIMENTAL","perioperative aspirin continuation",[13],"Drug: Aspirin",{"label":15,"type":16,"description":17,"interventionNames":18},"Interruption of Antiplatelet Therapy","ACTIVE_COMPARATOR","Interruption of aspirin 5-7 days before surgery",[19],"Drug: Aspirin interruption",[21,27],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Aspirin",[9],[26],"Aspirin (drug)",{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Aspirin interruption","Aspirin interruption 5-7 days before surgery",[15],[32],"Aspirin interruption (drug)",[34],{"name":35,"affiliation":36,"role":37},"Hiroki Shiomi, MD, PhD","Kyoto University Hospital","PRINCIPAL_INVESTIGATOR",[39,44],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+81-75-751-4255",null,"hishiomi@kuhp.kyoto-u.ac.jp",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Erika Yamamoto, MD, PhD","+81-75-751-4254","erkymmt@kuhp.kyoto-u.ac.jp",[49],{"facility":36,"status":50,"city":51,"state":42,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Kyoto","606-8507","Japan",{"type":55,"coordinates":56},"Point",[57,58],135.75385,35.02107,{"lat":58,"lon":57},[61],{"name":62,"role":40,"phone":41,"phoneExt":42,"email":43},"Hiroki Shiomi, MD",{"type":37,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Hiroki Shiomi","Hiroki Shiomi MD, PhD","100571660",false,"NCT06723145","Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation","OPERATION","Inclusion Criteria:\n\n* Patients with a history of coronary stenting and scheduled for abdominal surgery\n* Patients on a single antiplatelet agent\n\nExclusion Criteria:\n\n* Patients on dual antiplatelet therapy (DAPT)\n* Patients on anticoagulation therapy\n* Patients with a history of stent thrombosis\n* Patients with CHADS2 score \\>= 5\n* Patients at extremely high risk of bleeding and unable to continue preoperative aspirin\n* Patients incapable of consent, including those under 20 years of age\n* Other patients for whom either discontinuation or continuation of antiplatelet agents is deemed inappropriate by the attending physician","ALL","20 Years",{"count":75,"type":76},1200,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","The purpose of this study is to evaluate the impact of perioperative aspirin continuation on clinical outcomes in patients with a history of coronary stent implantation who are scheduled for abdominal surgery.",[82,83],"Antiplatelet Agents","Perioperative Care",[85,86,87,88,89],"antiplatelet agents","perioperative care","coroanry artery disease","abdominal disease","noncardiac surgery","2025-02-09",{"date":92,"type":93},"2025-02-11","ACTUAL",{"date":95,"type":93},"2025-01-20",{"date":97,"type":76},"2027-03-31",{"name":5,"class":6},1]